More recent large scale genomic studies have further defined the spectrum of genomic abnormalities in ERBB2-amplified HER2+ breast cancers, but the methods used for these studies precluded a detailed analysis of the large-scale genomic architecture of ERBB2-containing amplicons [41, 42]. This evidence concerns the gene ERBB2 and breast cancer.